Adherium announced that James Ward-Lilley who has been consulting to Adherium over recent months has joined the Adherium Board of Directors, and following the untimely death of Thomas Lynch, James has also been appointed Chairman of the Board. James has a very strong background and experience to bring to Adherium combining operational and executive leadership roles in the pharmaceutical and medical device industries across a range of therapy areas, including a deep knowledge of addressing respiratory diseases.James had an extensive global pharmaceutical career spanning 28 years across a range of primarily commercial roles at AstraZeneca before becoming Chief Executive Officer of Vectura Group PLC (the inhaled formulation and device development specialist) in September 2015.